The Limits of Personalized Medicine
By Timothy Caulfield,
The Atlantic
| 03. 16. 2016
Untitled Document
Personalized medicine—the idea that genetic testing can reveal a person’s unique risks for various illnesses, as well as the most effective treatments—has attracted a huge amount of attention over the past few years. While the concept includes promising approaches to things like cancer treatment, much of the focus has been on using genetic risk information to motivate healthy lifestyles. In his 2015 State of the Union address, President Obama suggested that future advances in biomedicine would provide the “personalized information we need to keep ourselves and our families healthier.” Francis Collins, the director of the National Institutes of Health, has suggested that personalized medicine “means taking better care of ourselves.”
In the context both men are describing—living healthier lifestyles to prevent chronic disease—the promise of personalized medicine lies in its ability to inspire behavior change. Having this genetic information isn’t inherently helpful; it’s what people do with the information that matters. But new research suggests that knowing one’s genetic risk isn’t enough to get people to quit smoking, eat better, or otherwise take actions to improve their health...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...